Brokerages Set Hikma Pharmaceuticals PLC (LON:HIK) Target Price at GBX 2,068.75

Shares of Hikma Pharmaceuticals PLC (LON:HIK) have earned an average recommendation of “Moderate Buy” from the six analysts that are presently covering the stock, Marketbeat Ratings reports. Three analysts have rated the stock with a hold rating and three have given a buy rating to the company. The average 12-month price objective among analysts that have issued ratings on the stock in the last year is GBX 2,068.75 ($25.75).

A number of analysts have issued reports on HIK shares. Barclays reiterated an “equal weight” rating and issued a GBX 2,000 ($24.90) target price on shares of Hikma Pharmaceuticals in a research note on Monday, April 8th. Berenberg Bank lifted their target price on shares of Hikma Pharmaceuticals from GBX 1,960 ($24.40) to GBX 2,000 ($24.90) and gave the company a “hold” rating in a research note on Monday, February 26th.

Hikma Pharmaceuticals Stock Performance

HIK stock opened at GBX 1,799 ($22.40) on Wednesday. The company has a debt-to-equity ratio of 53.92, a quick ratio of 1.27 and a current ratio of 1.57. The stock has a market cap of £3.99 billion, a P/E ratio of 2,685.07, a P/E/G ratio of 2.38 and a beta of 0.45. The firm has a 50 day simple moving average of GBX 1,900.77 and a 200 day simple moving average of GBX 1,877.24. Hikma Pharmaceuticals has a 52 week low of GBX 1,711 ($21.30) and a 52 week high of GBX 2,222 ($27.66).

Hikma Pharmaceuticals Increases Dividend

The company also recently declared a dividend, which will be paid on Friday, May 3rd. Stockholders of record on Thursday, March 21st will be given a $0.47 dividend. This is a positive change from Hikma Pharmaceuticals’s previous dividend of $0.25. The ex-dividend date of this dividend is Thursday, March 21st. This represents a dividend yield of 1.86%. Hikma Pharmaceuticals’s dividend payout ratio (DPR) is currently 8,507.46%.

Hikma Pharmaceuticals Company Profile

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables, Generics, and Branded. The Injectables segment provides generic injectable products primarily for use in hospitals.